We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Medicines Agency’s medical literature monitoring service kicked into full operation Tuesday, allowing drugmakers to easily search for information on adverse reactions associated with their products. Read More
Eli Lilly continued to beat back court challenges against Cymbalta, as a Virginia jury on Tuesday found the drugmaker not negligent in marketing its blockbuster antidepressant. Read More
Actavis must remove its generic version of Endo’s noncrush-resistant painkiller Opana from the U.S. market by Oct. 13, a New York federal judge ruled Aug. 14, citing infringement of Opana’s patents. Read More
Mylan scored a potential win from the U.S. Patent and Trademark Office when it agreed to review challenges to two patents on Teva’s blockbuster multiple schlerosis drug Copaxone. Read More
The Federal Trade Commission has reached a settlement with Par Pharmaceuticals and Concordia Pharmaceuticals that, if finalized, would prohibit them from restraining trade in the sale of generic Kapvay, an attention deficit hyperactivity disorder drug. Read More
The European Medicines Agency expects to receive the first generic drug application under a program that lets companies file joint submissions in the EU, Australia, Canada, Taiwan and Switzerland during the fourth quarter of this year. Read More
Australian regulators have approved Hospira’s Inflectra as the country’s first monoclonal antibody biosimilar, a version of Janssen’s autoimmune disease therapy Remicade. Read More
Amgen made a last-ditch effort to block competition for its chemotherapy product Neupogen, asking the Federal Circuit to stop Sandoz’s Sept. 2 launch of its Zarxio biosimilar. Read More
Just days before Sandoz is expected to launch Zarxio, its biosimilar of Amgen’s chemotherapy drug Neupogen, the FDA issued a proposed rule changing both drugs’ official names, at least temporarily. Read More
The FDA is seeking input on how it can make its Inactive Ingredients Database more useful and user-friendly, following complaints by generic drug and excipient makers that the current format delays ANDA filings. Read More
Industry questioned whether the FDA has the legal authority to enforce its quality metrics guidance during an Aug. 24 public meeting on the draft document. Read More